Bone Marrow and Stem Cell Transplantation

Bone marrow and stem cell transplantation encompasses a set of procedures that replace diseased or destroyed blood-forming cells with healthy stem cells capable of regenerating a functional hematopoietic system. These procedures are used across a range of hematologic malignancies, bone marrow failure syndromes, and select solid tumors. The field sits at the intersection of hematology, oncology, and immunology, and is subject to regulatory oversight from multiple federal agencies. Understanding the classification of transplant types, procedural phases, and patient selection criteria is essential for navigating the broader landscape of oncology care.

Definition and scope

Hematopoietic stem cell transplantation (HSCT) is the clinical process of infusing stem cells — collected from bone marrow, peripheral blood, or umbilical cord blood — to restore marrow function after high-dose chemotherapy, radiation, or marrow-ablating disease. The National Cancer Institute (NCI) classifies HSCT within its broader treatment taxonomy alongside chemotherapy, radiation therapy, and immunotherapy.

The Center for International Blood and Marrow Transplant Research (CIBMTR), a research collaboration between the Medical College of Wisconsin and the National Marrow Donor Program (NMDP), maintains outcome registries covering more than 500,000 transplant recipients. The CIBMTR database represents the primary epidemiological foundation for evidence-based transplant protocols in the United States.

The Health Resources and Services Administration (HRSA) oversees the C.W. Bill Young Cell Transplantation Program under 42 U.S.C. § 274k, which governs the national bone marrow registry and cord blood bank operations. Transplant centers performing HSCT must also meet accreditation standards set by the Foundation for the Accreditation of Cellular Therapy (FACT), which publishes joint accreditation standards with the Joint Accreditation Committee ISCT-EBMT (JACIE).

How it works

The HSCT process proceeds through four discrete phases:

Conditioning regimen — The patient receives high-dose chemotherapy, total body irradiation (TBI), or a reduced-intensity conditioning (RIC) regimen designed to eliminate malignant cells, suppress the immune system, and create marrow space for donor cells. Myeloablative conditioning (MAC) uses fully ablative doses; RIC uses attenuated doses intended to reduce toxicity in older or medically fragile patients.
Stem cell collection — Donor cells are harvested from one of three sources: (a) bone marrow, collected by aspiration from the posterior iliac crest under general anesthesia; (b) peripheral blood stem cells (PBSCs), mobilized using granulocyte colony-stimulating factor (G-CSF) and collected via apheresis; or (c) umbilical cord blood, collected at birth and stored in public or private cord blood banks. Peripheral blood stem cells are the most commonly used source in adult allogeneic transplants, according to CIBMTR annual data.
Infusion and engraftment — Collected stem cells are infused intravenously, migrating to marrow cavities where they engraft and begin producing red blood cells, white blood cells, and platelets. Neutrophil engraftment — typically defined as an absolute neutrophil count (ANC) ≥500/μL on 3 consecutive days — usually occurs between day 10 and day 28 post-infusion, depending on stem cell source and conditioning intensity.
Post-transplant monitoring — The period following infusion requires close surveillance for graft failure, infection, and graft-versus-host disease (GVHD). GVHD prophylaxis regimens, commonly involving calcineurin inhibitors such as tacrolimus or cyclosporine combined with methotrexate or mycophenolate mofetil, are guided by protocols developed under FACT accreditation standards and published NCI clinical trial data.

Common scenarios

HSCT is most frequently applied in the following clinical contexts:

Acute myeloid leukemia (AML) — Allogeneic transplant is a standard consolidation strategy in intermediate- and high-risk AML following first remission. For a deeper review of leukemia classification, see the dedicated reference page.
Acute lymphoblastic leukemia (ALL) — Allogeneic HSCT is used in high-risk ALL, Philadelphia chromosome-positive ALL, and relapsed or refractory ALL.
Lymphoma — Autologous HSCT remains a standard salvage option in relapsed diffuse large B-cell lymphoma (DLBCL) and relapsed Hodgkin lymphoma. The lymphoma reference page covers disease classification in detail.
Multiple myeloma — Autologous HSCT consolidation following induction chemotherapy is a widely adopted standard-of-care approach for transplant-eligible patients.
Aplastic anemia and bone marrow failure — Allogeneic HSCT from a matched sibling donor is the preferred treatment for severe aplastic anemia in patients under 40 years of age, per National Heart, Lung, and Blood Institute (NHLBI) clinical guidance.
Myelodysplastic syndromes (MDS) — Allogeneic HSCT is the only potentially curative option for higher-risk MDS, classified under the Revised International Prognostic Scoring System (IPSS-R).

Decision boundaries

The distinction between autologous and allogeneic transplantation defines the primary clinical and regulatory fork in HSCT decision-making.

Autologous transplantation uses the patient's own stem cells collected prior to high-dose therapy. It eliminates GVHD risk and immunosuppression requirements but cannot deliver a graft-versus-tumor (GVT) effect and carries risk of reinfusing residual malignant cells. It is standard in multiple myeloma and relapsed lymphoma.

Allogeneic transplantation uses stem cells from a matched related donor (MRD), matched unrelated donor (MUD), haploidentical donor, or cord blood. It provides a GVT immune effect capable of eradicating residual disease but introduces acute and chronic GVHD — a complication affecting 30–70% of allogeneic recipients depending on donor match and prophylaxis regimen (CIBMTR outcomes data). HLA matching at 8 of 8 alleles (HLA-A, -B, -C, DRB1) is the standard threshold for MUD selection through the NMDP/Be The Match registry.

Patient eligibility for transplant is also shaped by age, performance status, organ function, and comorbidity index scoring. The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), developed by Dr. Mohamed Sorror at the Fred Hutchinson Cancer Center, stratifies pre-transplant risk into low (score 0), intermediate (score 1–2), and high (score ≥3) categories, with 2-year non-relapse mortality rates varying substantially across these strata in published CIBMTR analyses.

The regulatory context for oncology governs how transplant centers must document protocols, maintain accreditation, and report outcomes to federal registries — all of which directly affect how HSCT programs operate within US health systems. Emerging cellular therapies, including CAR-T cell therapy, occupy an adjacent but distinct regulatory pathway under FDA's Center for Biologics Evaluation and Research (CBER), separately from conventional HSCT.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)